Related Experiment Video
Updated: Nov 7, 2025

MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues
Published on: November 30, 2013
Role of MicroRNA-145 in DNA Damage Signalling and Senescence in Vascular Smooth Muscle Cells of Type 2 Diabetic
Karen E Hemmings1,2, Kirsten Riches-Suman1,3, Marc A Bailey1,2
1Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds LS2 9JT, UK.
Abstract:
Increased cardiovascular morbidity and mortality in individuals with type 2 diabetes (T2DM) is a significant clinical problem. Despite advancements in achieving good glycaemic control, this patient population remains susceptible to macrovascular complications. We previously discovered that vascular smooth muscle cells (SMC) cultured from T2DM patients exhibit persistent phenotypic aberrancies distinct from those of individuals without a diagnosis of T2DM. Notably, persistently elevated expression levels of microRNA-145 co-exist with characteristics consistent with aging, DNA damage and senescence. We hypothesised that increased expression of microRNA-145 plays a functional role in DNA damage signalling and subsequent cellular senescence specifically in SMC cultured from the vasculature of T2DM patients. In this study, markers of DNA damage and senescence were unambiguously and permanently elevated in native T2DM versus non-diabetic (ND)-SMC. Exposure of ND cells to the DNA-damaging agent etoposide inflicted a senescent phenotype, increased expression of apical kinases of the DNA damage pathway and elevated expression levels of microRNA-145. Overexpression of microRNA-145 in ND-SMC revealed evidence of functional links between them; notably increased secretion of senescence-associated cytokines and chronic activation of stress-activated intracellular signalling pathways, particularly the mitogen-activated protein kinase, p38α. Exposure to conditioned media from microRNA-145 overexpressing cells resulted in chronic p38α signalling in naïve cells, evidencing a paracrine induction and reinforcement of cell senescence. We conclude that targeting of microRNA-145 may provide a route to novel interventions to eliminate DNA-damaged and senescent cells in the vasculature and to this end further detailed studies are warranted.
Insights
MicroRNA-145 promotes vascular smooth muscle cell senescence in type 2 diabetes by increasing DNA damage signaling. Targeting microRNA-145 may offer new treatments for cardiovascular complications in diabetes.
Area of Science:
- Vascular Biology
- Molecular Biology
- Endocrinology
Background:
- Type 2 diabetes (T2DM) significantly increases cardiovascular morbidity and mortality.
- Vascular smooth muscle cells (SMC) from T2DM patients show persistent abnormalities, including elevated microRNA-145, DNA damage, and senescence.
- Existing treatments focusing on glycemic control do not fully prevent macrovascular complications.
Purpose of the Study:
- To investigate the functional role of microRNA-145 in DNA damage signaling and cellular senescence in T2DM vascular SMC.
- To explore the potential of microRNA-145 as a therapeutic target for T2DM-associated vascular complications.
Main Methods:
- Comparison of DNA damage and senescence markers in T2DM versus non-diabetic (ND) SMC.
- Induction of senescence in ND-SMC using etoposide, a DNA-damaging agent.
- Overexpression of microRNA-145 in ND-SMC to assess its functional impact and signaling pathways.
Main Results:
- T2DM SMC exhibited elevated DNA damage and senescence markers compared to ND-SMC.
- Etoposide treatment induced senescence, increased DNA damage pathway kinases, and elevated microRNA-145 in ND-SMC.
- MicroRNA-145 overexpression in ND-SMC led to increased senescence-associated cytokine secretion and chronic p38α signaling, with conditioned media inducing senescence in naive cells.
Conclusions:
- Increased microRNA-145 expression contributes to DNA damage and cellular senescence in T2DM vascular SMC.
- MicroRNA-145 plays a functional role in promoting vascular senescence, potentially through paracrine signaling.
- Targeting microRNA-145 presents a promising strategy for developing novel interventions against vascular complications in type 2 diabetes.

